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compound that mimics the neuroprotective properties of bFGF – SUN11602 – were
examined in vitro and in vivo. SUN11602 promoted neurite outgrowth of primarily cultured
rat hippocampal neurons. For the in vivo study, an Alzheimer's disease (AD) model with
severe damage to the hippocampal tissue was constructed by injecting the hippocampi of
rats with aggregated Aβ1–40, followed 48 h later by an injection of ibotenate [an agonist
for N-methyl-D-aspartate (NMDA) receptor]. Oral administration of SUN11602 at the
midpoint of Aβ1–40 and ibotenate injections attenuated short-term memory impairment
in the Y-maze test, as well as spatial learning deﬁcits in the water maze task. In addition,
the SUN11602 treatment inhibited the increase of peripheral-type benzodiazepine-binding
sites (PTBBS), which are a marker for gliosis. A negative correlation was found between
PTBBS numbers and learning capacity in the water maze task. These results suggest that
SUN111602 improved memory and learning deﬁcits in the hippocampally lesioned rats by
preventing neuronal death and/or promotion of neurite outgrowth. Taken together, these
results indicate that SUN11602, a bFGF-like compound with neuroprotective and neurite
outgrowth activity, may be beneﬁcial for the treatment of progressive neurodegenerative
diseases such as AD.
& 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).3
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Alzheimer's disease (AD) is the leading cause of dementia and is
characterized by the progressive decline, and ultimately, loss, of
multiple cognitive functions (Fratiglioni et al., 1999; Small et al.,
1997). Characteristic neuroﬁbrillary tangles and deposits of Aβ
have been observed in the neocortical brain structures of AD
patients (Hardy and Higgins, 1992), and Aβ is believed to be a
pivotal mediator of neuronal degeneration, leading to impaired
cognitive function (Hardy, 2006; Mattson, 2004). In addition,
glutamate toxicity is involved in the pathogenesis of various
neurodegenerative disorders, including AD (Rothman and Olney,
1995). For example, glutamate transporter activity is decreased in
the postmortem brain of patients with AD (Masliah et al., 1996),
and cerebrospinal ﬂuid glutamate levels are higher in patients
with AD (Pomara et al., 1992).
The administration of bFGF into the hippocampus has been
shown to inhibit neuronal damage and spatial learning deﬁcits
in a rat model of AD (Noshita et al., 2012). In this study, Aβ1–40
peptide was injected into the hippocampus, followed by an
injection of ibotenate – an agonist of the N-methyl-D-aspartate
(NMDA) receptor – into the same site. The results of this study
therefore suggested that bFGF contributes to the treatment of
AD. However, bFGF is a bioactive peptide with a short half-life in
the blood and poor blood-brain barrier permeability. Further-
more, the administration of bFGF may lead to leukocytosis and
decreased blood pressure in humans (Bogousslavsky et al., 2002).
It is therefore critical to consider these physiological properties
when constructing strategies for the practical administration
of bFGF.
SUN11602 is a novel aniline derivative that exhibits bFGF-like
neuroprotective effects (Murayama et al., 2013). The speciﬁc FGF
receptor-1 (FGFR1) tyrosine kinase inhibitor PD166866 abolishes
the receptor-mediated neuroprotective effects elicited by
SUN11602. SUN11602 enhances the phosphorylation of FGFR1
and extracellular signal-regulated kinase 1/2 (ERK1/2) in cerebro-
cortical neurons. The pharmacokinetic properties of SUN11602 in
male Sprague Dawley (SD) rats and in male beagle dogs are
excellent, in that bioavailability of orally administered SUN11602
is465% in all animals investigated. Thus, it seems reasonable to
consider SUN11602 as a candidate compound for protecting
vulnerable neurons in various diseases of the central nervous
system.
We report here the ﬁnding that SUN11602, like bFGF,
induces neurite outgrowth of neurons. First, oral administra-
tion of SUN11602 improved cognitive performance in the
Y-maze and water maze tasks. Second, it decreased the
number of PTBBS, a gliosis maker, in the hippocampus of
an AD rat model induced by Aβ1–40 and ibotenate. These
ﬁndings indicate the therapeutic relevance of SUN11602 for
progressive neurodegenerative diseases such as AD.2. Results
2.1. Neurite outgrowth by SUN11602
The effect of SUN11602 on neurite outgrowth was examined
using primary cultures of rat hippocampal neurons (Fig. 1).Because neurite outgrowth could simply be secondary to
improved neuronal survival, we examined neurite length per
cell body, using the IN Cell Analyzer 1000 in the neurite out-
growth detection program. As shown in Fig. 1a, both bFGF and
SUN11602 apparently induced neurite outgrowth. The quantiﬁ-
cation of results revealed that SUN11602 signiﬁcantly increased
neurite outgrowth at a concentration of 1 μM, and the extent was
equivalent to the effect of bFGF at 1 ng/ml (Fig. 1b).
2.2. The effect of SUN11602 on cognitive deﬁcits
in hippocampal-lesioned rats: the Y-maze test
In our previous studies, we established a rat AD model with
hippocampal tissue damage, by using sequential treatments
with aggregated Aβ1–40 and ibotenate (Nakamura et al., 2006;
Noshita et al., 2012). We have shown that this model is useful
for evaluating pharmacological effects across histological,
behavioral, and biochemical analyses under a variety of
experimental conditions. In the present study, we investi-
gated the effect of SUN11602 on short term and spatial
working memory using this AD model. Fig. 2 shows the
results of the Y-maze test performed 32 days after adminis-
tration of Aβ1–40. The treatment of rats with Aβ1–40 and
ibotenate signiﬁcantly decreased the ratio of spontaneous
alterations (Fig. 2b), without affecting the total number of arm
entries (Fig. 2a), implying impaired working memory. A single
oral administration of SUN11602 24 h after the Aβ1–40 treat-
ment reversed the decrease in the spontaneous alteration
ratio in a dose-dependent manner, and this was statistically
signiﬁcant at 1 mg/kg. The administration of SUN11602 did
not affect the number of total arm entries (Fig. 2a).
2.3. The effect of SUN11602 on cognitive deﬁcits
in hippocampal-lesioned rats: the water-maze task
The water maze task was used to investigate learning and long-
term spatial reference memory, using the rat ADmodel induced
by Aβ1–40 and ibotenate. The task was performed over four days,
and commenced 35 days after the Aβ1–40 treatment. As shown
in Fig. 3a, the mean escape latency (MEL) recorded during the
acquisition training phase was signiﬁcantly prolonged by
sequential injections of Aβ1–40 and ibotenate into the hippo-
campus, demonstrating impaired learning. The administration
of SUN11602 inhibited the increased MEL induced by Aβ1–40 and
ibotenate (Fig. 3a). The effects of SUN11602 were statistically
signiﬁcant between days 2–4 and days 3–4 of the training
period, at 10mg/kg and 1mg/kg, respectively. In a single probe
trial performed 2 h after the ﬁnal acquisition trial, the number
of annulus crossings was signiﬁcantly decreased following
sequential injections of Aβ1–40 and ibotenate, indicating a
memory impairment. SUN11602 treatment showed a trend
toward inhibiting this decline in the number of annulus cross-
ings (Fig. 3b). SUN11602 did not affect the swimming speed of
rats (data not shown).
2.4. Protective effects of SUN11602 on hippocampal tissue
damage
Peripheral-type benzodiazepine-binding sites (PTBBS) have
been established as a quantitative marker for severity of
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Fig. 2 – Effects of SUN11602 on memory deﬁcits in hippocampal-lesioned rats induced by sequential injections of Aβ1–40 and
ibotenate (Y-maze test). (a) Total arm entries. (b) Percentage of spontaneous alterations. Each bar represents the mean7S.E.M.
The rats that completed 11 arm entries or less during the test were excluded from the experiments. The number of rats used
in the test is shown in parentheses. #po0.05 vs. the Sham group; nnnpo0.001 vs. the Vehicle group (Dunnett's multiple
comparison test).
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Fig. 1 – Effects of SUN11602 and bFGF on neurite outgrowth in hippocampal neurons. (a) Representative micrographs of the
cells treated with Control (left), 1 lM SUN11602 (middle), and 1 ng/mL bFGF (right). The scale bar is 100 μm. (b) Mean neurite
length per cell. Each bar represents the mean7S.E.M. The number of wells used is indicated in parentheses. npo0.05 vs. the
Control group (Dunnett's multiple comparison test).
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Venneti et al., 2006). We estimated the number of PTBBS
in vitro to quantify the extent of hippocampal tissue damagefollowing completion of the water maze task. The number of
PTBBS in the hippocampal tissue was signiﬁcantly increased
in the hippocampal-lesioned rats compared with a sham
Fig. 3 – Effects of SUN11602 on learning and memory deﬁcits in hippocampal-lesioned rats induced by sequential injections of
Aβ1–40 and ibotenate (water maze task). (a) Acquisition training was conducted over 4 consecutive days, as described in the
Experimental Procedure, and MEL (the mean time required to escape onto the hidden platform) was measured as a marker of
learning capacity. (b) A single probe trial was conducted 2 h after the ﬁnal training session on day 38, and the number of
crossings of the annulus, where the platform was located, was counted for 60 s and used as an index of memory retention.
Data represent the mean7S.E.M. The number of rats used is indicated in parentheses. #po0.05 vs. the Sham group (Student's
t test); npo0.05 vs. the Vehicle group (Dunnett's multiple comparison test).
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number of PTBBS in a dose-dependent manner, and this
effect was statistically signiﬁcant at Z1 mg/kg (Fig. 4a). There
was a high correlation between the number of PTBBS and
escape latency in the water maze task of sham rats and
hippocampal-lesioned rats (r¼0.73) (Fig. 4b).3. Discussion
The present study demonstrated the neuroprotective effects
of the novel aniline compound SUN11602 on rat hippocampal
neurons in vivo. SUN11602 also induced neurite outgrowth of
the primarily cultured hippocampal neurons, consistent with
the knowledge that bFGF accelerates neurite outgrowth and
branching of cultured hippocampal neurons (Ikegaya et al.,
2000; Katsuki et al., 2000).
It has been reported that transgenic mice overexpressing
human amyloid precursor protein do not show any signiﬁcant
neuronal cell loss, despite large accumulations of
ﬁbrillar Aβ (Games et al., 1995; Hsiao et al., 1996). These
observations suggest that Aβ alone is not sufﬁcient to cause
drastic neuronal loss, thus additional factors are necessary for
in vivo neurodegeneration. Glutamate transporter activity is
known to be decreased in the postmortem brain of patients
with AD (Masliah et al., 1996), and the level of glutamate in the
cerebrospinal ﬂuid in patients with AD is higher (Pomara et al.,
1992). We have previously shown that sequential injections of
aggregated Aβ1–40 and ibotenate (an NMDA receptor agonist)
into the hippocampus induces signiﬁcant neuronal cell death
and a learning deﬁcit in rats, while an injection of Aβ1–40 or
ibotenate alone at the same concentration does not
(Nakamura et al., 2006; Noshita et al., 2012). Others have also
reported similar synergistic effects of Aβ and glutamate on
neuronal cells, and suggested mechanisms include Aβ-induced
stimulation of intracellular Ca2þ inﬂux, rendering the neurons
vulnerable to excitotoxicity (Mattson et al., 1992). In an ADmodel in rats, where bilateral hippocampal formations were
sequentially treated with Aβ1–40 and ibotenate, we previously
revealed that parenchymal infusion of bFGF suppressed the
progression of tissue damage in the hippocampal formation,
and inhibited serious impairment to spatial learning ability
(Noshita et al., 2012). This ﬁnding indicated that bFGF was able
to rescue vulnerable hippocampal neurons from toxic condi-
tions, and restore neural function to the normal physiological
state. Such beneﬁcial functions of bFGF provide evidence for
the development of medication for a number of central
nervous system diseases and injuries, including AD. However,
it is necessary to address the problem regarding permeability
of the blood-brain barrier in the development of bFGF
treatment.
The present study focused on the protective activity of
hippocampal neurons treated with SUN11602 (orally) under
an in vivo toxic condition. In the Y-maze test, which is used
to investigate short-term or spatial working memory, the
injection of Aβ1–40 followed by ibotenate into the hippocam-
pus decreased the ratio of spontaneous alteration, an index of
memory, and this decrease was inhibited by treatment with
SUN11602. Importantly, SUN11602 had virtually no effect on
the total number of arm entries, indicating that its effect was
independent of changes in spontaneous locomotor activity.
In the water maze task, used to examine learning and spatial
reference memory, rats injected with Aβ1–40 and ibotenate
showed not only learning deﬁcits in the training session
(prolonged MEL), but also memory alterations (a decrease in
the number of annulus crossings in a single probe trial).
SUN11602 improved this learning impairment and also
showed a trend to promote memory retention. This is con-
sistent with previous ﬁndings that bFGF improves cognitive
recovery in the water maze test using the same lesion model
(Noshita et al., 2012), as well as in rats following traumatic
brain injury (Sun et al., 2009). The effect of SUN11602 was
unrelated to the swimming ability of the rats, based on the
absence of a difference in swimming speed between groups.
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Fig. 4 – Effect of SUN11602 on neuronal damage in
hippocampal-lesioned rats induced by sequential injections
of Aβ1–40 and ibotenate. The number of PTBBS, as an index of
gliosis, was measured in the hippocampus of rats after
completion of the water maze task, as described in the
Experimental Procedure. (a) Effect of SUN11602 on the
numbers of PTBBS (mean7S.E.M.). ##po0.01 vs. the Sham
group (Student's t test); nnpo0.01 vs. the Vehicle group
(Dunnett's multiple comparison test). The number of rats
used is indicated in parentheses. (b) Correlation between
PTBBS numbers and escape latency in the water maze task
of each lesioned rat. Symbols show the data for each rat. The
correlation coefﬁcient (r) was 0.73.
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ber of PTBBS in rats, and SUN11602 treatment signiﬁcantly
attenuated their level. PTBBS have been employed as a
reliable marker to demonstrate brain injury, and their num-
bers increase dramatically following brain lesions, reﬂecting
the severity of gliosis in damaged brain tissue (Venneti et al.,
2006). Changes in PTBBS numbers are therefore thought to be
associated with neuronal damage, which would be followed
by the activation of microglia to scavenge the injured tissue
(Baudry and Altar, 1991). In this study, it was observed that
the injection of Aβ1–40 and ibotenate into rats induced an
increase in the number of PTBBS, i.e. neuronal damage, and
this was inhibited with SUN11602 treatment. Moreover, we
found a correlation between the number of PTBBS and
learning capacity (measured as escape latency during the
training session) in hippocampal-lesioned rats treated withSUN11602. Collectively, it is thought that the improvement of
memory and learning deﬁcits observed in the model rats
treated with SUN11602 might be, at least in part, due to
protection against neuronal death.
The mechanism for the effects of SUN11602 on learning
and memory deﬁcits might also be explained by promotion of
neurite outgrowth. For example, it has been reported that
acute subcutaneous injection of bFGF 15 min before beha-
vioral conditioning enhances long term memory in normal
developing rats (Graham and Richardson, 2009). Furthermore,
intracerebroventricular injection of bFGF for 2 weeks
enhances production and dendritic growth of new dentate
granule cells in the middle-aged hippocampus (Rai et al.,
2007). Interestingly, these ﬁndings suggest that bFGF, as well
as SUN11602, might enhance learning ability in naïve rats
similar to the effect observed in impaired rats, although we
did not examine the effect of SUN11602 using normal rats in
the present study. Another potential mechanism could be the
promotion of long-term potentiation. This is because bFGF
has been found to promote the generation process of long-
term potentiation (Ishiyama et al., 1991), that is considered to
correlate with learning and memory ability and is impaired
by the Aβ peptide (Barry et al., 2011). It is important to note
that we need to examine the mechanism of SUN11602 using
the disease model in future.
In conclusion, the novel compound SUN11602 could,
like bFGF, play a beneﬁcial role in neuroprotection and
neurite outgrowth in damaged hippocampal tissue. Since
SUN11602 could overcome the limitations of the administra-
tion protocol for bFGF, this compound might be a promising
and useful therapeutic agent for various central nervous
system disorders.4. Experimental procedure
4.1. Reagents
SUN11602 (4-({4-[[(4-Amino-2,3,5,6-tetramethylanilino)acetyl]
(methyl)amino]-1-piperidinyl}methyl)benzamide) was syn-
thesized at Asubio Pharma Co., Limited (Murayama et al.,
2013). The marker, 3H-PK11195, was purchased from the
Japan Radioisotope Association. All other reagents were
obtained from Nacalai Tesque, Inc. (Kyoto, Japan).4.2. Animals
Male F344/DuCrj rats aged 10 weeks and weighing 220–250 g
at the beginning of the experiments were obtained from
Charles River Laboratories Japan, Inc. (Tokyo, Japan). Female
SLC:Wistar pregnant rats were obtained from Japan SLC, Inc
(Shizuoka, Japan) and used in the experiments involving
primary cultures of rat hippocampal neurons. Experiments
were carried out according to the NIH guidelines for the care
and use of laboratory animals, and were approved by the
Ethics Committee for Animal Experiments of the Biomedical
Research Laboratories, Asubio Pharma Co., Ltd. The rats were
housed in an artiﬁcially controlled room (2372 1C and
55715% humidity) with food and water available ad libitum,
b r a i n r e s e a r c h 1 5 8 5 ( 2 0 1 4 ) 1 5 9 – 1 6 6164under a 12 h light/dark cycle (lights on at 07:00). Experiments
were carried out between 08:30 and 16:30.
4.3. Preparation of primary cultures of rat neurons
Hippocampal neurons were prepared from the brains of
embryonic Wistar rats (embryonic day 18 [E18]) for neurite
outgrowth tests. After the brains were dissected, the hippo-
campi were dissociated with papain and suspended in Neu-
robasal medium (Invitrogen, Carlsbad, CA) containing 5%
NuSerum (Japan BD, Tokyo, Japan) and 2% B27 (Invitrogen).
After dissociation, hippocampal neurons were seeded on
poly-D-lysine-coated 48-well plates (Falcon, Becton, Dickinson
and Company, Franklin Lakes, NJ) at high density (approxi-
mately 120 cells/mm2 in 48-well plates) and cultivated in
Dulbecco's modiﬁed Eagle's medium (DMEM; Gibco, Life
Technologies Japan Ltd., Tokyo, Japan) supplemented with
10 mM NaHCO3, 15 mM KCl, and 1 mM sodium pyruvate. In
addition, 5% (v/v) Nu-serum (Becton, Dickinson and Com-
pany) was added to the medium for hippocampal neurons.
The neuronal cultures were maintained in an atmosphere of
10% CO2 at 37 1C in a humidiﬁed incubator. Four days after
seeding, the proliferation of non-neuronal cells was inhibited
by addition of 1 μM arabinofuranosyl cytidine (Ara-C; ﬁnal
concentration). The subsequent experiments were performed
after 7 days. The purity of the cultures was 495% as
determined by NeuN-speciﬁc immunostaining.
4.3.1. Quantiﬁcation of neurite outgrowth
Procedures for immunocytochemistry were carried out
according to accepted protocols and the manufacturer's
instructions. In brief, either SUN11602 (ﬁnal concentration;
0.1, 0.3, and 1 μM) or bFGF (ﬁnal concentration; 1 ng/mL) was
added to the culture of rat primary hippocampal neurons in
poly-D-lysine-coated 48-well microplates on days 3 and 5. The
neuronal culture was then ﬁxed on day 7 with 2% parafor-
maldehyde and 4% sucrose in 0.1 M sodium phosphate buffer
(pH 7.4) for 15 min. After treatment in 5% goat-serum block-
ing solution (Vector Laboratories, CA, USA) for 30 min at room
temperature, neurons were incubated with primary antibo-
dies against MAP-2 (1:5000; #ab5392, Abcam, Cambridge, UK)
for 24 h at 4 1C. After several rinses, the neurons were
incubated with Alexa Fluor 488 goat anti-chicken IgG as the
secondary antibody (1:1000; # A11039; Life technologies, Japan
Ltd., Tokyo, Japan). Quantiﬁcation of neurite length and
number of neurons were measured using an automated
image acquisition and analysis system (IN Cell Analyzer
1000; Amersham Biosciences, Uppsala, Sweden) in the neur-
ite assay. Immunoﬂuorescence labeling of the MAP-2 was
used to detect neurites and cell bodies of neurons.
4.4. Generation of the rat hippocampal-lesion model by
sequential injections of Aβ140 and ibotenate
A solution of 4 mg/mL Aβ1–40 (Peptide Institute Inc., Japan) was
prepared with saline containing 2 mM HCl and incubated
for 7 days at 37 1C. The solution was distinctly turbid,
and 480% of the peptide could be precipitated by centrifuga-
tion (15,000g, 10 min). Ibotenic acid (Sigma-Aldrich,St. Louis, MO) was dissolved in phosphate-buffered saline
(0.6 mg/mL, ibotenate solution).
A hippocampal lesion was induced as described previously
(Nakamura et al., 2006) but with a slight modiﬁcation. Brieﬂy,
F344 rats were anesthetized with pentobarbital sodium
(50 mg/kg i.p., Nembutals; Dinabott, Tokyo, Japan) and placed
in a stereotaxic apparatus. The skull was exposed and small
holes (1 mm in diameter) were made in the parietal bone (3.0
and 4.5 mm posterior to the bregma, and one hole72.0 mm
and73.5 mm lateral to the midline each, giving a total of four
holes) under a surgical microscope, to avoid excessive irrita-
tion to the meninges and underlying brain. The aggregated
Aβ1–40 (1 mL at 4 mg/mL) was injected bilaterally into the
hippocampus using a 30-gauge needle through these holes
(totaling four injection sites), according to the coordinates of
the rat neuroanatomical atlas of Paxinos and Watson (1986).
A volume of 1 mL was injected at a ﬂow rate of 0.25 mL/min for
4 min using a CMA/100 microsyringe pump. The 30-gauge
needle was left in place for 2.5 min after the injection, before
being withdrawn; subsequently, the surgical wound was
sutured and the animals were returned to their home cages.
Forty-eight hours later, ibotenate solution (0.5 mL at 0.6 mg/mL)
was injected at a ﬂow rate of 0.125 mL/min for 4 min in the
same manner and using the same coordinates at which Aβ1–40
was injected. In sham rats, an injection cannula was inserted
into the above-mentioned position, without injecting the
physiological saline. After surgery, the rats were kept in
their home cages with free access to chow and water.
The hippocampal-lesioned model rats were evaluated using
the Y-maze test (day 32), the water maze task (days 35–38),
and PTBBS measurement (after completion of the water
maze task).
4.4.1. Administration of SUN11602
SUN11602 (0.1, 1, and 10 mg/kg) was administered orally
to the rat hippocampal-lesion model, once at 24 h after the
Aβ1–40 injection. In the vehicle-treated groups, saline was
administered instead of SUN11602.
4.4.2. The Y-maze test
The Y-maze test in the hippocampal-lesioned rats was
performed 32 days after the injection of Aβ1–40. The apparatus
was manufactured from black plastic with three arms
extending from a central platform at 1201. Each rat was
placed at the end of one arm and allowed to move freely
through the maze during a session that lasted 8 min. Arm
entry was deﬁned as all four of the animal's paws entering
one arm. The sequence of arm entries was recorded visually.
Alternation was deﬁned as multiple entries into the three
arms (A, B, or C) on overlapping triplet sets. The rats that
were observed to have 11 arm entries or less during the test
were excluded from the experiments. The percentage of
spontaneous alternations was calculated as: Alternation
(%)¼ [(number of alternations)/(total arm entries2)]100.
4.4.3. The water maze task
The water maze task in the hippocampal-lesioned rats was
performed according to the method of Morris (1981). The
apparatus consisted of a circular water tank with a diameter
of 132 cm and a depth of 60 cm. The interior surface of the
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depth of 45 cm with water (2472 1C) that was clouded with
0.8 kg of powdered milk. A translucent acrylic platform (10 cm
diameter) was submerged 2 cm below the water surface in
the center of one of the four quadrants of the maze. The tank
was located in a large room with multiple external cues
(including a computer, breeding cages, a calendar, and black
and white graphics.). The position of the cues and the plat-
form was constant throughout the study. The movement of
the animal in the tank was monitored using a video tracking
system (VIOS-88, Biomedica, Japan) and analyzed on a
computer.
The acquisition training study was carried out over 4
consecutive days, 35–38 days after the Aβ1–40 injection. On
the ﬁrst day of acquisition, each rat was placed into the tank
without an escape platform and allowed to swim for 60 s.
Maze training began 3–4 h later. In each trial, the rat was put
into the water at 1 of 4 starting points (north, east, south, or
west) located on the edge of the tank. The starting point was
changed between trials in a quasi-random manner, whereas
the escape platform was ﬁxed throughout the acquisition
training. The time required to escape onto the hidden plat-
form was recorded for each trial. If the rat found the platform,
it was allowed to remain there for 10 s. If it did not ﬁnd the
platform within 120 s, the trial was terminated and the
experimenter placed the rat onto the platform and allowed
it to stay there for 10 s. The rats were trained for 4 days, with
4 trials per day, performed at 60 s intervals. A single probe
trial was conducted 2 h after the ﬁnal training session. For
this trial, the escape platform was removed and each rat was
allowed to swim for 60 s in the maze. The number of cross-
ings of the annulus where the platform had been located was
recorded.4.4.4. Measurement of PTBBS
The hippocampal-lesioned rats were decapitated under ether
anesthesia immediately after completion of the water maze
task, and the brain was quickly excised. Peripheral-type
benzodiazepine-binding sites (PTBBS) were measured as an
index of gliosis and neuronal damage (Baudry and Altar,
1991). The hippocampi were dissected out on ice and stored
at 80 1C until the assay. PTBBS were measured according to
the method of Demerle-Pallardy et al. (1991). In brief, [3H]–
PK11195 (3163.5 GBq/mmol; NEN, Boston, MA) was used as a
radiolabeled ligand for PTBBS, and the amount of this reagent
that was bound to the crude hippocampus membrane was
measured. The hippocampal tissue samples were homoge-
nized in 40 volumes of homogenate buffer (50 mM Tris–HCl
and 120 mM NaCl, pH 7.4). [3H]–PK11195 was added to a ﬁnal
concentration of 2 nM and the samples were incubated at
25 1C for 60 min. The samples were then immediately ﬁltered
on a Whatman glass ﬁber ﬁlter (GF/B) and washed 3 times
with 5 mL of ice-cold buffer. Radioactivity on the ﬁlter was
measured using a liquid scintillation counter (TRI-CARB
1900CA, PACKARD), and the amount of ligand bound to cell
membranes was calculated by subtracting the nonspeciﬁc
binding in the presence of PK11195 (1 mM) from the total
binding. Furthermore, the protein content of the tissue
sample was determined using the method of Smith et al.(1985) and the level of ligand per mg of protein (fmol/mg
protein) was calculated.4.5. Statistical analyses
Data were presented as means7S.E.M. Two-way analysis of
variance (ANOVA) followed by post-hoc testing was per-
formed. Student's t test, Dunnett's multiple comparison test,
were carried out using EXSUS version 7.5.2 software (Arm
Systex Co., Ltd, Osaka, Japan). Statistical signiﬁcance was set
at po0.05. Correlation coefﬁcients (r) were calculated using
the same software.Conﬂict of Interests
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